Concord Drugs Stock Price Today (NSE: 538965)
Fundamental Score
Concord Drugs Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Concord Drugs share price today is ₹73.40, up +2.37% on NSE/BSE as of 7 August 2026. Concord Drugs (538965) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹92.37 (Cr). The 52-week high for 538965 share price is ₹92.52 and the 52-week low is ₹49.00. At a P/E ratio of 88.82x, 538965 is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 2.52% and a debt-to-equity ratio of 0.24.
Concord Drugs Share Price Chart — NSE/BSE Historical Performance
Concord Drugs share price chart: -0.85% return over the past month. 52-week high ₹92.52, 52-week low ₹49.00.
Concord Drugs — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹71.00 | ₹73.75 | ₹71.00 | ₹73.40 | 1.81K (Cr) | |
| ₹74.49 | ₹74.49 | ₹70.11 | ₹71.70 | 1.25K (Cr) | |
| ₹71.35 | ₹72.80 | ₹71.00 | ₹71.23 | 3.47K (Cr) | |
| ₹76.00 | ₹78.00 | ₹69.41 | ₹70.26 | 17.66K (Cr) | |
| ₹74.62 | ₹74.62 | ₹72.17 | ₹74.00 | 32.82K (Cr) | |
| ₹72.03 | ₹75.47 | ₹71.16 | ₹75.00 | 4.05K (Cr) | |
| ₹68.20 | ₹81.99 | ₹68.20 | ₹72.98 | 23.80K (Cr) | |
| ₹67.93 | ₹70.94 | ₹65.06 | ₹68.89 | 7.70K (Cr) | |
| ₹71.90 | ₹71.90 | ₹64.00 | ₹67.93 | 8.37K (Cr) | |
| ₹73.00 | ₹73.00 | ₹69.15 | ₹70.00 | 3.48K (Cr) |
Concord Drugs — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹76.00 | ₹78.00 | ₹69.41 | ₹73.40 | -3.42% | |
| ₹75.01 | ₹81.99 | ₹64.00 | ₹74.00 | -1.35% | |
| ₹87.00 | ₹87.00 | ₹71.70 | ₹75.64 | -13.06% | |
| ₹84.55 | ₹87.98 | ₹77.00 | ₹82.39 | -2.55% | |
| ₹70.23 | ₹89.00 | ₹68.00 | ₹85.13 | +21.22% | |
| ₹76.99 | ₹79.95 | ₹68.05 | ₹70.23 | -8.78% | |
| ₹75.94 | ₹88.00 | ₹71.11 | ₹79.00 | +4.03% | |
| ₹82.50 | ₹91.79 | ₹67.25 | ₹70.34 | -14.74% | |
| ₹83.36 | ₹88.50 | ₹70.42 | ₹82.48 | -1.06% | |
| ₹69.04 | ₹92.52 | ₹66.00 | ₹83.36 | +20.74% | |
| ₹66.70 | ₹71.50 | ₹61.00 | ₹69.04 | +3.51% | |
| ₹64.99 | ₹71.00 | ₹59.66 | ₹66.70 | +2.63% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Concord Drugs Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Concord Drugs Fundamental Analysis & Valuation Benchmarking
Educational evaluation of 538965 across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Robust Profit Growth (5100.00%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (346.61%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Strong Profit Growth Track Record (21.06% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.24)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Balanced Promoter Holding (54.39%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
6 factors identified
Below-Average Return on Equity (2.52%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (5.24%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 88.82x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Weak Interest Coverage (1.99x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-7.08 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Concord Drugs vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Concord Drugs with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
48/100 | ₹73.40₹73 | ₹92.37₹92.37 | 88.82Average 88.8 Average | 2.52%Poor 2.52% Poor | 5.24%Poor 5.24% Poor | 0.24Excellent 0.2 Excellent | 21.06%Excellent 21.06% Excellent | 8.12%Good 8.12% Good | 0.00% | |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Concord Drugs Quarterly Performance
Latest quarterly metrics for 538965 — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
346.61%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
5100.00%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
8.12%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
21.06%
Compounded annual net profit growth over 5 years
Concord Drugs Technical Indicators
SMA 50, SMA 200, RSI and volume signals for 538965 — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Concord Drugs Financial Statements
Annual income statement, balance sheet and cash flow for Concord Drugs (538965) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Concord Drugs
About 538965 (Concord Drugs)
Concord Drugs (538965) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current ma...rket capitalisation of ₹92.37 (Cr). Concord Drugs has delivered a Return on Equity (ROE) of 2.52% and a ROCE of 5.24%. The debt-to-equity ratio stands at 0.24, reflecting the company's capital structure. Investors tracking 538965 share price can monitor key metrics including P/E ratio, promoter holding of 54.39%, and quarterly earnings growth.
Company Details
538965 Share Price: Frequently Asked Questions
What is the current share price of Concord Drugs?
Concord Drugs (538965) trades at ₹73.40 on BSE. Market cap ₹92.37 (Cr). Educational data only.
What is the P/E ratio of Concord Drugs?
Concord Drugs has a P/E of 88.82x vs industry average 34.89x.
What is the Bull Run score for Concord Drugs?
Concord Drugs has a Bull Run score of 48/100 based on 25+ financial parameters.
Does Concord Drugs pay dividends?
Concord Drugs has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Concord Drugs?
Concord Drugs has ROE of 2.52%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Concord Drugs?
Concord Drugs has debt-to-equity of 0.24.
Is Concord Drugs a good investment?
Bull Run gives Concord Drugs a score of 48/100. This is not investment advice — consult a SEBI-registered advisor.